A qualitative and quantitative analysis of the Diabetes Drugs Market

The global diabetes drugs market derives growth from advancements in drug delivery systems. According to a report published by Fortune Business Insights, titled "Diabetes Drugs: Global Market Analysis, Insights and Forecast, 2019-2026," the market was valued at US$ 48,753.1 Mn in 2018. Fortune Business Insights has predicted that the market will be valued at US$ 78,261.7 Mn by the end of 2026, thereby exhibiting a CAGR of 6.1%.

Availability of Low-Cost Insulin to Boost the Market

Insulin is one of the most widely used drugs for the treatment of diabetes. The exceptional properties and clinical efficacy of insulin have led to a rising uptake. Despite high efficacy, the cost associated with insulin has been a barrier towards the growth of insulin. Considering this factor, many companies are exploring potential ways to the reduced cost associated with insulin for management of diabetes.

In 2019, Eli Lilly and Company, launched a new insulin drug, that was almost half the price of its previous brands. Eli Lilly announced the low-cost insulin 'Lispro', a product that was priced significantly less than its previous Humalog injection. Fortune Business Insights' latest report on the global diabetes drugs market is an encompassment of such product advancements. The report gauges the impact of product innovations, similar to Lispro, on the global market.

Get Sample PDF Brochure@ https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/diabetes-drugs-market-100570

Company profiled in this report based on Business overview, Financial data, Product landscape, Strategic outlook & SWOT analysis:

o Novo Nordisk A/S
o Sanofi
o Merck & Co., Inc.
o Eli Lilly and Company
o AstraZeneca
o Takeda Pharmaceutical Company Limited
o Boehringer Ingelheim International GmbH
o Novartis AG
o Johnson & Johnson Services, Inc.
o Bayer AG

Encouraged by High Demand, Glenmark Extends Insulin Sales in India

In 2019, Glenmark Pharmaceuticals announced that it plans to bring its Remogliflozin Etabonate to India. The high demand for diabetes drugs in India has influenced Glenmark's latest move. Additionally, a huge diabetic patient pool has also contributed to the high demand for diabetes drugs in India.

Such competitor moves have aided the growth of the global diabetes drugs market. The report includes company activities, similar to the aforementioned case. The report includes detailed analysis of company activities such as takeovers, mergers and acquisitions, agreements, and investment.

Increasing Drug Approvals Have a Positive Impact on Overall Market

The high prevalence of diabetes on a global scale has paved way for several clinical trials. Increasing drug approvals have aided the growth of the global diabetes drugs market. Novo Nordisk's 2018 launch of Ozempic and Fiasp is a perfect example of the aforementioned case. Additionally, the company received approval from the Food and Drug Administration and this has aided the business expansion of Novo Nordisk. The company's latest drug approvals will bode well for the global diabetes market and is likely to enable growth of the market in the coming years.

Fortune Business Insights has summarized the impact of several companies on the global diabetes drugs market. Furthermore, Fortune Business Insights has labelled out leading companies that have made significant contributions to the growth of the global diabetes drugs market.

Order Full Report@ https://www.fortunebusinessinsights.com/checkout-page/100570

Market Segmentations:

By Route of Administration
o Oral
o Subcutaneous
o Intravenous

By Distribution Channel
o Online pharmacies
o Hospital Pharmacies
o Retail Pharmacies

By Geography
o North America (U.S. and Canada)
o Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
o Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
o Latin America (Brazil, Mexico, and Rest of Latin America)
o Middle East & Africa (South Africa, GCC, and Rest of Middle East & Africa)

More Trending Topics:

MRI Systems Market 2020 - https://www.medgadget.com/2020/01/mri-systems-market-2020-worldwide-research-and-clinical-trends-to-watch.html

Molecular Diagnostics Market 2025 - https://www.medgadget.com/2020/01/top-research-and-clinical-trends-in-molecular-diagnostics-market-2025.html

Dialyzer Market 2020 - https://www.medgadget.com/2020/01/dialyzer-market-2020-geographical-overview-global-trends-industry-analysis-top-players-and-forecast-till-2026.html

Fortune Business Insights(TM) offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

At Fortune Business Insights(TM) we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

Fortune Business Insights(TM) Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune - 411045, Maharashtra, India.

Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com
Fortune Business Insights(TM)
Linkedin | Twitter | BLogs

This release was published on openPR.